Loading…
Enlivex Ltd. is projected to rise to $2.67 by 2027, a +23% move from its current price of $2.17. ENLV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.05 | $2.17 | $2.30 | -0.07% |
| Aug 6 | $2.00 | $2.17 | $2.35 | -0.13% |
| Aug 7 | $1.96 | $2.17 | $2.40 | -0.20% |
| Aug 8 | $1.93 | $2.16 | $2.43 | -0.26% |
| Aug 9 | $1.90 | $2.16 | $2.46 | -0.33% |
| Aug 10 | $1.87 | $2.16 | $2.49 | -0.40% |
| Aug 11 | $1.85 | $2.16 | $2.52 | -0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.85 | $2.16 | $2.52 | -0.46% |
| Week 2 | $1.73 | $2.15 | $2.68 | -0.92% |
| Week 3 | $1.64 | $2.14 | $2.80 | -1.38% |
| Week 4 | $1.56 | $2.13 | $2.90 | -1.84% |
| Week 5 | $1.50 | $2.12 | $3.00 | -2.29% |
| Week 6 | $1.45 | $2.11 | $3.08 | -2.74% |
| Week 7 | $1.40 | $2.10 | $3.16 | -3.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial.
The company also develops AllocetraTM intra-articular injection for osteoarthritis of the temporomandibular joint (TMJ) and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd.
and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Enlivex Ltd. (ENLV) is a healthcare company trading with a current price of $2.09 and a market capitalization of $35.18M. It holds a position in the market with a rank of 4641. The price outlook is embedded in a multi-year forecast showing limited movement in 2026, followed by bullish upside in subsequent years, with average prices increasing from $2.09 in 2026 to higher levels by 2030, 2040, and 2050.
Key forecast milestones include 2026 average price of $2.09, 2027 average $2.58, 2028 average $2.85, 2029 average $2.90, 2030 average $2.57, 2034 average $3.63, 2035 average $3.89, 2040 average $4.21, and 2050 average $7.05. Forecasted ROIs range from 0% in 2026 to 237.4% in 2050, with sentiment moving from NEUTRAL to BULLISH over the longer horizon.
A major floor 77.8% below — a decisive break under it would weaken the trend.
The nearest floor, 10.1% below — buyers have tended to step in here.
The nearest ceiling, 330.6% above — a clean break opens room to run.
A major ceiling 372.0% above — clearing it would confirm fresh momentum.
Key ENLV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENLV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.56 | Sell | $2.56 | Sell |
| MA 10 | $3.53 | Sell | $3.14 | Sell |
| MA 20 | $3.95 | Sell | $3.23 | Sell |
| MA 50 | $1.99 | Buy | $2.45 | Sell |
| MA 100 | $1.45 | Buy | $1.84 | Buy |
| MA 200 | $1.23 | Buy | $1.47 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.11 | Neutral |
| Stoch RSI (14) | 3.65 | Buy |
| CCI (20) | -70.34 | Neutral |
| Williams %R (14) | -96.59 | Info |
| MACD (12,26,9) | -0.46 | Sell |
| ROC (12) | -64.21 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 3.41 | Buy |
| TRIX (15) | 4.13 | Buy |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 13.72 | Buy |
| Momentum (10) | -2.59 | Sell |
| Aroon Osc (25) | 4.00 | Buy |
| Hull MA (9) | 1.51 | Buy |
| ADX (14) | 32.00 | Sell |
| ATR (14) | 0.41 | Info |
The 30-day technical picture shows a NEUTRAL sentiment with RSI14 at 10, indicating an oversold condition. The stock trades with a 30-day range from $1.42 to $3.07, and it sits near the $1.95 support level while facing $9.35 resistance. The SMA50 is $8.13 and the SMA200 is $13.01, signaling a backdrop of weak upward pressure relative to longer-term averages.
Annualized volatility stands at 100%, underscoring pronounced near-term swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.95 | $2.17 | $2.90 | 0% | Neutral | |
| $1.95 | $2.67 | $3.96 | +23% | Bullish | |
| $2.02 | $2.96 | $4.68 | +36% | Bullish | |
| $1.97 | $3.02 | $5.03 | +39% | Bullish | |
| $1.64 | $2.65 | $4.59 | +22% | Bullish | |
| $1.59 | $2.68 | $4.80 | +23% | Bullish | |
| $1.43 | $2.51 | $4.65 | +16% | Neutral | |
| $1.30 | $2.37 | $4.51 | +9% | Neutral | |
| $1.97 | $3.75 | $7.32 | +73% | Bullish | |
| $2.04 | $4.05 | $8.07 | +86% | Bullish | |
| $1.96 | $4.36 | $9.56 | +101% | Bullish | |
| $3.31 | $7.35 | $16.91 | +239% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.95 | $2.17 | $2.65 | +0.00% |
| September 2026 | $1.64 | $1.99 | $2.53 | -8.16% |
| October 2026 | $1.66 | $2.04 | $2.64 | +2.51% |
| November 2026 | $1.78 | $2.21 | $2.91 | +8.35% |
| December 2026 | $1.73 | $2.17 | $2.90 | -1.79% |
Click any year to see its month-by-month ENLV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ENLV could reach as high as $2.90, with a base case around $2.17 and support toward $1.95 — roughly 0% from $2.17. Price action looks broadly range-bound.
Expect ENLV to range from $1.95 to $3.96 through 2027. The $2.67 average target implies a +23% move from current prices. That is up +23% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ENLV price prediction for 2028 points to an average of $2.96 (low $2.02, high $4.68) — a potential gain of +36% on today's $2.17. Momentum favours further upside here.
In 2029, ENLV is projected to trade between $1.97 and $5.03, averaging $3.02 — a potential gain of +39% from today's $2.17. That is up +2% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Enlivex Ltd.'s 2030 outlook centres on $2.65, within a $1.64 to $4.59 range. That is -12% versus the projected 2029 average. That marks a +22% change versus current levels. Momentum favours further upside here.
By 2031, ENLV could reach as high as $4.80, with a base case around $2.68 and support toward $1.59 — roughly +23% from $2.17. Buyers look set to stay in control over this stretch.
Expect ENLV to range from $1.43 to $4.65 through 2032. The $2.51 average target implies a +16% move from current prices. That is -6% versus the projected 2031 average. Price action looks broadly range-bound.
The ENLV price prediction for 2033 points to an average of $2.37 (low $1.30, high $4.51) — a potential gain of +9% on today's $2.17. A consolidation phase looks the most probable path here.
In 2034, ENLV is projected to trade between $1.97 and $7.32, averaging $3.75 — a potential gain of +73% from today's $2.17. That is up +58% on the projected 2033 average. Momentum favours further upside here.
Enlivex Ltd.'s 2035 outlook centres on $4.05, within a $2.04 to $8.07 range. That is up +8% on the projected 2034 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ENLV could reach as high as $9.56, with a base case around $4.36 and support toward $1.96 — roughly +101% from $2.17. Momentum favours further upside here.
Expect ENLV to range from $3.31 to $16.91 through 2050. The $7.35 average target implies a +239% move from current prices. That is up +69% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ENLV today (≈ 460.829493 ENLV) could be worth
$3,387.67
+$2,387.67 (+239%) by 2050 · US Dollar
Based on the average projected ENLV price of $7.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENLVwould be worth at today's price.
$1,000 invested in ENLV on Jul 31, 2025 (≈ 671.140935 ENLV) would be worth
$1,456.38
+$456.38 (+45.6%) today · 1.46× · US Dollar
Based on a ENLV entry price of $1.49 vs. today's $2.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.2 | $516.67 | -48.3% |
| 1 month ago | $0.542 | $4,003.69 | +300.4% |
| 3 months ago | $0.816 | $2,659.31 | +165.9% |
| 6 months ago | $1.04 | $2,086.54 | +108.7% |
| 1 year ago | $1.49 | $1,456.38 | +45.6% |
| All time (5.0y) ago | $8.3 | $261.45 | -73.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENLV forecast.
Our base-case forecast reaches $4.30 around 2040.
Implied market cap at $4.30: $72.38M
The multi-year forecast paints a bullish path beyond 2026, with notable upside in the years ahead. The 2030 average price is $2.57 with a max of $4.44 and a 22.8% ROI, indicating meaningful, but bounded, upside from current levels. By 2040 the forecast envisions an average of $4.21 with a max of $9.23 and a 101.4% ROI, suggesting substantial growth if the program progresses.
In 2050 the average is projected at $7.05 with a max of $16.22 and a 237.4% ROI, reflecting potential long-term value creation but also significant uncertainty and volatility.
Drivers include the company’s Allocetra-based immunotherapies and ongoing trial programs for knee and TMJ osteoarthritis as well as sepsis-related organ failure; risks include the early-stage nature of clinical programs and the inherent volatility of small-cap healthcare stocks. These figures are estimates, not guarantees, and should be interpreted with caution as actual results may differ.
Tap a question to reveal the answer.
2030 forecast shows an average price of $2.57 with a range of $1.59 to $4.44 and a 22.8% ROI; sentiment is BULLISH.
Forecasts show a NEUTRAL stance in 2026, then BULLISH from 2027 onward, with ROIs of 23.5% (2027), 36.3% (2028), 38.8% (2029), and 22.8% (2030), culminating in stronger upside by 2040 and 2050, though these are estimates and come with significant risk.
The max forecast in 2050 is $16.22, so a $10 target would be within the long-term upside if the forecast materializes.
Current price is $2.09 and market cap is $35.18M.
2040 forecast shows a min of $1.89, an average of $4.21, and a max of $9.23 with a 101.4% ROI; sentiment is BULLISH.
Enlivex Ltd. Community Discussion
0Share your Enlivex Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.